Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 11,562 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CHRONIC DISEASE Clear all
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 31, 2026, 3:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis

NCT00691366
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)

NCT02078960
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Omacetaxine mepesuccinate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1 Interventional

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

NCT00562380
View directory record Official record
Conditions
Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ganitumab, laboratory biomarker analysis, pharmacological study, biopsy
Biological · Other · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 31, 2026, 3:02 AM EDT
Recruiting Not applicable Interventional

Improving Sleep in Veterans With the Polytrauma Clinical Triad

NCT06477796
View directory record Official record
Conditions
Traumatic Brain Injury, Post-traumatic Stress Disorder, Chronic Pain
Interventions
Morning Bright Light Therapy, Negative Ion Generator
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Recruiting Not applicable Interventional

Combination Therapy to Improve SCI Recovery.

NCT05563103
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Daily acute intermittent hypoxia, Room air (SHAM), Walking + tSTIM, Walking + Sham transcutaneous spinal stimulation (tSHAM)
Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 2 Interventional

Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

NCT00045422
View directory record Official record
Conditions
Leukemia
Interventions
recombinant interferon alfa, imatinib mesylate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

NCT04707573
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Not applicable Interventional

Nu-V3 Non-Invasive Nerve Stimulation Device Trial for Chronic Pain, Anxiety, Depression, Sleeplessness

NCT05335980
View directory record Official record
Conditions
Chronic Pain, Anxiety, Depression, Sleeplessness
Interventions
Nu-V3
Device
Lead sponsor
Nu-Life Solutions
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 31, 2026, 3:02 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05023980
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Pirtobrutinib, Bendamustine, Rituximab
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Whittier, California • Coral Springs, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Completed No phase listed Observational

Capsaicin Cough Threshold in Chronic Cough Due to Postnasal Drip

NCT00588627
View directory record Official record
Conditions
Post Nasal Drip
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2010 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Phase 2 Interventional

Dietary Intervention and Exercise Training (DIET) in Moderate to Severe Chronic Kidney Disease

NCT00581269
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
low-impact aerobic exercise, low-calorie (low-fat) diet
Behavioral · Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 2 Interventional

A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE)

NCT01490879
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Nexagon® Low Dose, Nexagon® Medium Dose, Nexagon® High Dose, Nexagon® vehicle
Drug
Lead sponsor
OcuNexus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Oct 31, 2026, 3:02 AM EDT
Active, not recruiting Not applicable Interventional

Feasibility and Effectiveness of Therapy Together

NCT07225673
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Therapy Together - 4 hour group, Therapy Together - 1 hour group
Behavioral
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
3 Months to 59 Months
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Not applicable Interventional

Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness

NCT01244854
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Chronic Affective Disorders, Cardiovascular Disease Risk
Interventions
Life Goals Collaborative Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1 Interventional

Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation

NCT00383994
View directory record Official record
Conditions
Lymphoma, Leukemia, Transplantation, Stem Cell, Lymphoid Malignancies, Disorder Related to Transplantation
Interventions
GM-CSF, Rituximab, NK Cell Infusion
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

NCT00250679
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions
Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
60
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 31, 2026, 3:02 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

NCT05692596
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas, Genetic Pancreatic Cancer, Genetic Pancreatitis, BRCA Mutation, Lynch Syndrome, FAP, Familial Atypical Multiple Mole-Melanoma, PALB2 Gene Mutation, Peutz-Jeghers Syndrome, Ataxia Telangiectasia
Interventions
Data collection
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

A Study of Renal Microvessel Imaging for Chronic Kidney Disease

NCT05764642
View directory record Official record
Conditions
Healthy, Chronic Kidney Diseases
Interventions
Definity, Super-resolution ultrasound imaging
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 31, 2026, 3:02 AM EDT
Recruiting Not applicable Interventional

Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups

NCT06974773
View directory record Official record
Conditions
Endometriosis
Interventions
NettleEndo, Sham NettleEndo Device
Device
Lead sponsor
Samphire Group, Inc.
Industry
Eligibility
22 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 31, 2026, 3:02 AM EDT
Terminated Phase 2 Interventional

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00005641
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 31, 2026, 3:02 AM EDT
Completed Phase 1Phase 2 Interventional

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

NCT00093366
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
etanercept, arsenic trioxide
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 31, 2026, 3:02 AM EDT
Withdrawn Phase 2 Interventional

Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

NCT00485966
View directory record Official record
Conditions
B-Cell Chronic Lymphocytic Leukemia
Interventions
CX-3543
Drug
Lead sponsor
Cylene Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Scottsdale, Arizona • Beverly Hills, California • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2008 · Synced Oct 31, 2026, 3:02 AM EDT